RFS in AML patients in morphologic CR depending on the number of leukemic cells in BM aspirate, assessed by immunophenotype, after intensification treatment. The two groups of patients are as follows: (A) ≥2 × 10⁻³ leukemic cells (n = 13), with a median survival of 16 months; and (B) less than 2 × 10⁻³ leukemic cells (n = 25), in which the median survival has not been reached. The date of BM aspirate after intensification treatment was considered as day 0 for RFS analysis.